MedTrace Logo

PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer

NCT07607119 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2026-05-26

No results posted yet for this study

Summary

The purpose of this prospective, single-center, phase II study is to evaluate the clinical efficacy and safety of combining first-line systemic therapy plus immunotherapy with personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR) in patients with unresectable locally advanced gastric cancer.

Conditions

  • Gastric Adenocarcinoma
  • Stomach Neoplasms
  • Locally Advanced Gastric Cancer
  • Unresectable Gastric Cancer

Interventions

RADIATION

PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy)

Dose Schedule: 6 Gy per fraction administered every 3-4 weeks

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-15
Primary Completion
2028-04-30
Completion
2030-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07607119 on ClinicalTrials.gov